Search Result

Results for "

26b pde Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (451) 5-HT Receptor (1) Adenosine Deaminase (2) Adenosine Receptor (11) Adrenergic Receptor (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (43) ATTECs (1) Aurora Kinase (1) Autophagy (23) Bacterial (7) Beta-secretase (1) Biochemical Assay Reagents (2) Calcium Channel (8) Calmodulin (1) Casein Kinase (2) Cholinesterase (ChE) (3) Cytochrome P450 (2) Dopamine Receptor (1) Drug Metabolite (3) E1/E2/E3 Enzyme (1) EGFR (3) Endogenous Metabolite (21) Fungal (2) GABA Receptor (1) Glucocorticoid Receptor (2) GLUT (1) GPR35 (1) GSK-3 (2) HDAC (9) Histamine Receptor (3) HIV (6) IKK (3) Influenza Virus (3) Interleukin Related (9) Isotope-Labeled Compounds (19) JAK (1) mAChR (7) MAPKAPK2 (MK2) (1) MicroRNA (12) MMP (1) Molecular Glues (4) Monoamine Oxidase (1) mTOR (2) Na+/H+ Exchanger (NHE) (1) NF-κB (2) NO Synthase (7) Nuclear Factor of activated T Cells (NFAT) (1) Parasite (2) Phosphatase (1) PKA (9) PKG (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (2) PPAR (2) Prostaglandin Receptor (1) RAR/RXR (1) Ras (6) Reactive Oxygen Species (3) RSV (5) Small Interfering RNA (siRNA) (53) Sodium Channel (3) TNF Receptor (16) Toll-like Receptor (TLR) (1) Wnt (3) β-catenin (2)
By Research Areas:	Cancer (132) Cardiovascular Disease (105) Endocrinology (29) Infection (15) Inflammation/Immunology (162) Metabolic Disease (33) Neurological Disease (123)
Oligonucleotides:	miRNA mimics (3) miRNA agomirs (3) miRNA antagomirs (3) MicroRNAs (12) Pre-designed siRNA Sets (53) miRNA inhibitors (3) siRNAs (53)

550

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Phosphodiesterase (PDE) Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-R00497

*hsa-miR-26b-5p mimic*	MicroRNA	Cancer
hsa-miR-26b-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-26b-5p mimic hsa-miR-26b-5p mimic

HY-R00496

*hsa-miR-26b-3p mimic*	MicroRNA	Cancer
hsa-miR-26b-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-26b-3p mimic hsa-miR-26b-3p mimic

HY-R02857

*mmu-miR-26b-3p mimic*	MicroRNA	Cancer
mmu-miR-26b-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-26b-3p mimic mmu-miR-26b-3p mimic

HY-RI00496

*hsa-miR-26b-3p inhibitor*	MicroRNA	Cancer
hsa-miR-26b-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-26b-3p inhibitor hsa-miR-26b-3p inhibitor

HY-RI00497

*hsa-miR-26b-5p inhibitor*	MicroRNA	Cancer
hsa-miR-26b-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-26b-5p inhibitor hsa-miR-26b-5p inhibitor

HY-RI02857

*mmu-miR-26b-3p inhibitor*	MicroRNA	Cancer
mmu-miR-26b-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-26b-3p inhibitor mmu-miR-26b-3p inhibitor

HY-R00496A

*hsa-miR-26b-3p agomir*	MicroRNA	Cancer
hsa-miR-26b-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-3p agomir hsa-miR-26b-3p agomir

HY-R00497A

*hsa-miR-26b-5p agomir*	MicroRNA	Cancer
hsa-miR-26b-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-5p agomir hsa-miR-26b-5p agomir

HY-R02857A

*mmu-miR-26b-3p agomir*	MicroRNA	Cancer
mmu-miR-26b-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-26b-3p agomir mmu-miR-26b-3p agomir

HY-RI00496A

*hsa-miR-26b-3p antagomir*	MicroRNA	Cancer
hsa-miR-26b-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-3p antagomir hsa-miR-26b-3p antagomir

HY-RI00497A

*hsa-miR-26b-5p antagomir*	MicroRNA	Cancer
hsa-miR-26b-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-5p antagomir hsa-miR-26b-5p antagomir

HY-RI02857A

*mmu-miR-26b-3p antagomir*	MicroRNA	Cancer
mmu-miR-26b-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-26b-3p antagomir mmu-miR-26b-3p antagomir

HY-128574

GLUT4 activator 1	GLUT	Metabolic Disease
GLUT4 activator 1 (Compound 26b) is a potent glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM .

HY-148234

M4K2234	Anaplastic lymphoma kinase (ALK)	Cancer
M4K2234 (compound 26b) is an ALK2 inhibitor. M4K2234 inhibits ALK2 and ALK5 with IC₅₀s of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for ALK1 and ALK2 protein kinases. M4K2234 can be used for the research of cancer .

HY-W171611

PDE-IN-3	Phosphodiesterase (PDE)	Neurological Disease
PDE-IN-3 (compound 23) is a phosphodiesterase (PDE) inhibitor with an IC₅₀ of 260 μM .

HY-149661

PDE5-IN-11	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-11 is a potent inhibitor of *PDE5* with an IC₅₀ of 40 nM. PDE5-IN-11 also inhibits *PDE4* and *PDE6* with IC₅₀s of 1.78 and 0.09 μM, respectively .

HY-162583

PDE4-IN-17	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-17 (compound 4e) is a potent *PDE4* inhibitor. PDE4-IN-17 inhibits *PDE4B* and *PDE4D* with IC₅₀s of 10.0 and 15.2 nM, respectively. PDE4-IN-17 has good oral bioavailability (F=66%) and longer half-life (t_1/2=2.0 h) in SD rats .

HY-E70514

Human CYP26B1,Low-Reductase	Cytochrome P450	Neurological Disease
Human CYP26B1, Low-Reductase, a recombinant CYP26B, is a member of the CYP enzyme family. CYP26B1 is important for the development and differentiation of the central nervous system (especially the hindbrain) and skeletal development .

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6 LPS, from Escherichia coli (O26:B6)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from E. coli O26:B6 is a lipopolysaccharide endotoxin and TLR-4 activator that activates the disease-related molecular pattern (PAMP) of the immune system and induces cell secretion of migratory bodies. Lipopolysaccharides, from E. coli O26:B6 consists of an antigen-specific O-chain, some cells lack an O-antigen-side chain, and is recognized by the core-specific monoclonal antibody MAb J8-4C10 .

HY-U00427

PDE2/PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and *PDE10* inhibitor with IC₅₀s of 29 and 480 nM, respectively.

HY-RS07280

KIF26B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KIF26B Human Pre-designed siRNA Set A contains three designed siRNAs for KIF26B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KIF26B Human Pre-designed siRNA Set A KIF26B Human Pre-designed siRNA Set A

HY-RS15680

VPS26B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
VPS26B Human Pre-designed siRNA Set A contains three designed siRNAs for VPS26B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS26B Human Pre-designed siRNA Set A VPS26B Human Pre-designed siRNA Set A

HY-RS03448

CYP26B1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP26B1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP26B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP26B1 Human Pre-designed siRNA Set A CYP26B1 Human Pre-designed siRNA Set A

HY-128060

PDE5-IN-42	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-42 (Compound 42) is a potent and orally active *PDE5* inhibitor with an IC₅₀ of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11 .

HY-101490

PDE1-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE1-IN-2 is a *PDE1* inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .

HY-124388

PDE4-IN-20	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-20 is a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor with anti-TNF-α properties. PDE4-IN-20 exhibits significant biological activity in vitro and in vivo. The mechanism of action of PDE4-IN-20 is supported by molecular modeling studies, which reveal its binding mode with PDE4. PDE4-IN-20 was optimized in further conformational analysis and showed pharmacological characteristics similar to those of known PDE4 inhibitors .

HY-W787896

PDE4-IN-25	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-25 (compound 12) is a potent inhibitor of *PDE4*，with the IC₅₀ of 0.1 μM. PDE4-IN-25 plays an important role in inflammatory diseases research .

HY-130262

PDE1-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-3, compound 4 (WO2019156861), is a selective human phosphodiesterase 1 (PDE1) inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC₅₀ values of 23.99 μM and 10 μM, respectively .

HY-131710

PDE5-IN-3	Phosphodiesterase (PDE) EGFR Wnt Apoptosis	Cancer
PDE5-IN-3 (compound 11j) is a potent *PDE5* inhibitor with an IC₅₀ of 1.57 nM. PDE5-IN-3 shows moderate EGFR inhibition with IC₅₀ of 5.827 µM. PDE5-IN-3 significantly inhibits the Wnt/β-catenin pathway (IC₅₀=1286.96 ng/mL). PDE5-IN-3 induces the intrinsic apoptotic mitochondrial pathway in HepG2 cells. PDE5-IN-3 has strong antitumor activity .

HY-161290

PDE5-IN-12	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-12 (compound 4h) is a potent phosphodiesterase-5 (PDE-5) inhibitor with an IC₅₀ of 22 nM. PDE5-IN-12 shows anti-proliferative effects against the aortic cell line .

HY-50865

PDE-9 inhibitor	Phosphodiesterase (PDE)	Neurological Disease
PDE-9 inhibitor is useful for neurodegenerative diseases.

HY-153766

PDE5-IN-9	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-9 (Compound 59) is a *PDE5* inhibitor (IC₅₀: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease .

HY-159654

PDE4-IN-19	Phosphodiesterase (PDE)	Others
PDE4-IN-19 (compound 1) is a *PDE4* inhibitor, with IC₅₀ values of <10 nM and 10-100 nM for PDE4B1 and PDE4D3, respectively .

HY-153733

PDE5-IN-8	Phosphodiesterase (PDE)	Cancer
PDE5-IN-8 (compund 2) is a *PDEs* inhibitor .

HY-147950

PDE4-IN-10	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4-IN-10 (compound 7a) is a potent *PDE4* inhibitor, with an IC₅₀ of 7.01 μM for *PDE4B. PDE4-IN-10 shows selectivity, microsomal stability, inhibition of TNF-α* and no major toxicities in vitro .

HY-155830

PDE4-IN-14	Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PDE4-IN-14 (Compound 1) is a *PDE4* inhibitor that can be used in the study of PDE4-related diseases (such as inflammatory and immune diseases, cancer, and metabolic diseases, etc.) .

HY-147946

PDE1-IN-4	Phosphodiesterase (PDE) Calcium Channel	Inflammation/Immunology
PDE1-IN-4 (compound 2g) is a potent and selective *PDE1* (phosphodiesterase-1) inhibitor, with IC₅₀ values of 10, 145, and 354 nM for *PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE*1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-115913

PDE4-IN-6	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-6 is a potent, safe and moderately selective *PDE4* inhibitor with IC₅₀s of 0.125 and 0.43 µM for PDE4B and PDE4D, respectively. PDE4-IN-6 can downregulate the expression level of TNF-α and IL-6. PDE4-IN-6 has potent immunomodulatory activity thereby its potential against rheumatoid arthritis. Anti-inflammatory and anti-arthritic effects .

HY-112704

PDE5-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-2 is a potent, highly selective, and orally active *PDE5* inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for *PDE4* and *PDE7, respectively (SI=2.71 and 4.27, respectively). PDE*4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-100326

PDE7-IN-3	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Pde7-in-3 (example 2) is an inhibitor of the phosphodiesterase *PDE7* with potential analgesic activity. PDE7-IN-3 can be used to study inflammatory, neuropathic, visceral and nociceptive pain .

HY-146974

PDE4-IN-9	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-9 (Compound 5j) is a potent inhibitor of *PDE4. PDE4-IN-9 exhibits lower IC₅₀* value (1.4 μM) against PDE4 than parent rolipram (2.0 μM) in in vitro enzyme assay. PDE4-IN-9 also displays good in vivo activity in animal models of asthma/COPD and sepsis induced by LPS .

HY-117318

PDE12-IN-1	Phosphodiesterase (PDE)	Infection
PDE12-IN-1 is a potent and selective *PDE12* inhibitor with a pIC₅₀ value for enzyme inhibition of 9.1. PDE12-IN-1 increases 2′,5′-linked adenylate polymers (2-5A) levels, and the pEC₅₀ value is 7.7. PDE12-IN-1 shows antiviral activity .

HY-169402

PDE1-IN-9	Phosphodiesterase (PDE) NO Synthase Reactive Oxygen Species	Inflammation/Immunology
PDE1-IN-9 (Compound 7a) is a selective inhibitor for phosphodiesterase 1 (PDE1), that inhibits *PDE1C* with an IC₅₀ of 11 nM. PDE1-IN-9 reduces mRNA expression of IL-1β, IL-6, TNF-α and iNOS, inhibits the production of nitric oxide (NO) and reactive oxygen species (ROS). PDE1-IN-9 exhibits good metabolic stability in rat liver microsomes .

HY-112555

PDE7-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC₅₀ value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease .

HY-148625

PDE9-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE9-IN-2 (compound 6) is a *PDE9* inhibitor that improves heart failure.

HY-W011336

PDE5-IN-7	Phosphodiesterase (PDE)	Others
PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC₅₀ value of 5 nM, while an IC₅₀ of 300 nM for PDE 1 .

HY-155692

PDE4-IN-13	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-13 is a *PDE4* inhibitor with an IC₅₀ of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties， and can be used for chronic obstructive pulmonary disease (COPD) research .

HY-163406

PDE1-IN-6	Phosphatase Apoptosis	Cancer
PDE1-IN-6 (compound 6c) is a selectivity *PDE1* inhibitor with the IC₅₀ of 7.5 nM. PDE1-IN-6 significantly inhibits the proliferation and induced cell apoptosis in Acute myelogenous leukemia cells .

HY-161506

PDE1-IN-7	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-7 (Compound 13h) is a selective inhibitor of bPDE1 (IC₅₀= 10 nM). PDE1-IN-7 exhibits significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model. PDE1-IN-7 can be used for research in liver fibrosis .